Ftse Mib
38.472,56
0,00%
DAX
22.425,93
0,73%
S&P 500
5.983,25
-0,50%
NASDAQ
19.286,92
-1,21%
Bitcoin
90.304,71
-1,22%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Abeona Therapeutics Inc (ABEO) Abeona Therapeutics Inc (ABEO) Notizie

ABEO

Abeona Therapeutics (ABEO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABEO
DataOraFonteTitoloSimboloCompagnia
04/02/202502:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABEOAbeona Therapeutics Inc
03/02/202513:30GlobeNewswire Inc.Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ABEOAbeona Therapeutics Inc
29/01/202522:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABEOAbeona Therapeutics Inc
06/01/202523:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ABEOAbeona Therapeutics Inc
20/12/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABEOAbeona Therapeutics Inc
15/11/202401:56Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ABEOAbeona Therapeutics Inc
14/11/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABEOAbeona Therapeutics Inc
14/11/202413:30GlobeNewswire Inc.Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesNASDAQ:ABEOAbeona Therapeutics Inc
12/11/202423:24Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ABEOAbeona Therapeutics Inc
12/11/202413:30GlobeNewswire Inc.Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis BullosaNASDAQ:ABEOAbeona Therapeutics Inc
04/11/202413:30GlobeNewswire Inc.Abeona Therapeutics® Announces Participation in November Investor ConferencesNASDAQ:ABEOAbeona Therapeutics Inc
29/10/202412:30GlobeNewswire Inc.Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug AdministrationNASDAQ:ABEOAbeona Therapeutics Inc
03/09/202413:30GlobeNewswire Inc.Abeona Therapeutics® Announces Participation in Upcoming Investor ConferencesNASDAQ:ABEOAbeona Therapeutics Inc
14/08/202423:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABEOAbeona Therapeutics Inc
14/08/202413:30GlobeNewswire Inc.Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of DirectorsNASDAQ:ABEOAbeona Therapeutics Inc
13/08/202413:30GlobeNewswire Inc.Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-celNASDAQ:ABEOAbeona Therapeutics Inc
12/08/202413:30GlobeNewswire Inc.Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA ResubmissionNASDAQ:ABEOAbeona Therapeutics Inc
11/07/202413:30GlobeNewswire Inc.Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology IndicationsNASDAQ:ABEOAbeona Therapeutics Inc
08/07/202413:30GlobeNewswire Inc.Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy ForumNASDAQ:ABEOAbeona Therapeutics Inc
17/06/202423:17Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ABEOAbeona Therapeutics Inc
12/06/202413:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ABEOAbeona Therapeutics Inc
03/06/202422:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABEOAbeona Therapeutics Inc
03/06/202413:30GlobeNewswire Inc.Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ABEOAbeona Therapeutics Inc
28/05/202413:30GlobeNewswire Inc.Abeona Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:ABEOAbeona Therapeutics Inc
15/05/202413:30GlobeNewswire Inc.Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate ProgressNASDAQ:ABEOAbeona Therapeutics Inc
13/05/202423:03Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ABEOAbeona Therapeutics Inc
03/05/202413:30GlobeNewswire Inc.Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:ABEOAbeona Therapeutics Inc
22/04/202422:05GlobeNewswire Inc.Abeona Therapeutics Provides Regulatory Update on Pz-celNASDAQ:ABEOAbeona Therapeutics Inc
18/03/202412:30GlobeNewswire Inc.Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsNASDAQ:ABEOAbeona Therapeutics Inc
01/02/202413:30GlobeNewswire Inc.Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)NASDAQ:ABEOAbeona Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABEO

La tua Cronologia

BIT
11COV
Bearer
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci